Our People

A successful entrepreneur and CEO with more than two decades of leading private and public companies, Ian has successfully led the turnaround, re-capitalization and listing of several businesses, returning them to profit. He holds a Business Education Diploma from the University of Newcastle, and a Licentiateship (LCGI) (NVQ Level 4) from the Royal Navy.

With a wealth of experience in financial services, including institutional fund management within the Lloyd’s of London insurance community, and HNW private client stockbroking at Popes Stockbrokers (now Brewin Dolphin), Kieran has an indepth knowledge of the private capital markets, involving capital raising, investor relations and communication, and is responsible for the fund-raising activities at Deepbridge. Kieran has been a Fellow of the Chartered Institute of Securities and Investments since 2001.

Through his position on the Investment Supervisory Committee, Kieran acts as a conduit between the Executive Team at Deepbridge and the Independent Committee Team, thus ensuring the Independent Committee have access to all information required to assist them in making sound and strategic investment decisions on a timely basis.

Savvas is the Head of Life Sciences at Deepbridge. Prior to joining Deepbridge, Savvas enjoyed a 15 year career in the City, working as an investment banker at JP Morgan, Bear Stearns, Shore Capital, Cantor Fitzgerald, and Panmure Gordon. Savvas was also CEO of telemedicine business Now Healthcare Group.  As a highly acclaimed analyst, Savvas has won multiple awards, most recently in 2015 when Savvas was ranked 2nd overall in the prestigious Reuters Starmine survey, a position he also held in 2014. In the same year, Savvas was also runner-up in the CityAM Analyst of the Year awards. Savvas holds a PhD in psychopharmacology from Nottingham University and a BSc (Hons) degree in pharmacology from Manchester University.

Ray is an experienced capital markets professional having spent over two decades working for some of the largest banks and broking houses in the world.

He has held senior positions across a variety of disciplines including; trading, portfolio management, private banking and corporate finance with institutions such as Garban Intercapital (now ICAP), Prudential-Bache, Barclays Wealth, and Coutts & Co.

Ray works closely with sophisticated investors, private offices and institutional funding partners, as well as providing corporate finance support to later-stage portfolio investee companies.

Rick is currently Chairman of the English Football League, former CEO of the FA Premier League, and former CEO of Liverpool Football Club. During Rick’s twelve years at Liverpool FC, the club won ten trophies, including the UEFA Champions League. Since leaving Liverpool FC in 2009, Rick has chaired The Sports Betting Integrity Panel for the UK Government and has travelled extensively in North America and the Middle East and is now on the Board of the New York Cosmos. With high-level proven management expertise, Rick brings an unrivalled depth of market insight to the Deepbridge Team.

Adrian has a MSc in Computer Science (A.I and Machine learning) from Trinity College Dublin, a MBA from Dublin City University and is a graduate of the London Business School. He has gained considerable experience of working with tech-focussed innovations and developing business transformation strategies.

Adrian’s previous roles include 10 years as IT Director at Hewlett Packard and 7 years as CEO of an Irish government commercial organisation where he introduced AWS in 2011 to dramatically reduce operating costs whilst broadening content. Most recently, Adrian has been Commercial Director at Trinity College Dublin where he grew the business from 15.2 million annual EBITDA to 28 million in 5 years. Adrian has also been an early stage investor in many USA technology start-ups where he gained valuable experience on how to scale tech-focused innovations.

Bernard has over 20 years of senior experience at private & public board level across multiple industries including pharmaceutical, technology development and FMCG. A former Head of International Development at CMI plc, Senior Vice President, Cardiovascular at Bioaccelerate Inc. (NASDAQ:BACL), CEO Inncardio Inc., CEO Accura Pharma plc. Bernard is Founder and CEO of Sky Medical Technology, a medical bioelectronics technology company.  Sky Medical Technology has received funding via the Deepbridge Technology Growth EIS.

Over 20 years of experience in the biotechnology sector, Chris has founded, managed and successfully exited two biotechnology companies, Bioenvision Inc. (NASDAQ:BIV, which grew to a market capitalization of $345 million, and was acquired by Genzyme Corporation in October 2007), and Medirace Limited (later Medeva PLC, traded on both the London Stock Exchange and the New York Stock Exchange, and subsequently acquired by Celltech Group PLC, now UCB, for £554 million). An Honorary Professor at Imperial College London, Chris holds an M.D. from the University of Wales School of Medicine, and is a Fellow of the Royal College of Surgeons of Edinburgh.

Gary graduated from Trinity College, Dublin with MB BCh BAO, in 1997. Subsequently he undertook training in various medical specialities prior to being awarded AFRCSI from Royal College of Surgeons, Ireland in 2001. Subsequently he undertook general practice training in the Mersey Deanery and was awarded Merit in the MRCGP examinations 2006. Further he studied at Manchester University to obtain Certificate of Occupational Health. Gary has been a GP Principal and Partner in an 8000 patient practice in Cheshire. This experience gives him an understanding of front-line medical services and a distinct insight into the needs of patients and clinicians. Gary is also clinical lead for Primary Care, a Governing Body member at Halton CCG and has been selected to study on the Nye Bevan program at the NHS leadership Academy.

Geoff is the Chief Executive of Bionow, the life sciences membership organisation for the North of England. Having founded the business in 2011, Bionow has 15 University members and 300 industry members across the North of England and North Wales. Geoff is regularly invited to advise and comment on industry requirements and represent the Bionow membership both regionally and nationally. Previously, Geoff founded 2 biotech companies, Biorite Ltd and Advanced Biomedical Ltd, both spin-out companies from the University of Manchester focused on developing point of care diagnostic technologies. Geoff has a degree in Biochemistry and a PhD from the School of Pharmacy, University of Manchester where he began his career undertaking postdoctoral research in the area of enhanced payload responsive liposomal drug delivery systems.

Geoff is also a Board Member and Treasurer of the Academy of Pharmaceutical Sciences, a member of the Liverpool LEP Health and Life Sciences Advisory Board, member of Health Innovation Manchester Exec group and member of Northeast LEP Health and Life Sciences Advisory Board.

Jim is an experienced Business Leader within a proven track record of delivery of significant business growth, expansion and business consolidate in both large and start-up businesses.  Jim is CEO & founder of Firestar Science and Technology, a product development advisory business in the healthcare sector.  Further to graduating with a BSc in Biochemistry, Jim’s considerable previous experience includes healthcare roles with organisations such as Siemens and Microvisk.

Liz has a degree in Chemistry and a DPhil in Physical Chemistry from the University of Oxford. She joined the commercial team in a startup company spun-out of Oxford University, and built-up expertise in intellectual property management and IP strategy. Later Liz spent 7 years at the University of Reading as their IP/Legal Advisor. Then in 2012 Liz joined Science & Technology Facilities Council as Licensing Manager. She is based at the STFC Rutherford Appleton Laboratory and now forms part of the STFC innovation management team with responsibility for a portfolio of spin-out companies and licensing deals at both Rutherford Appleton Laboratory and Sci-Tech Daresbury.

Lloyd co-founded, launched and scaled Zesty from an idea in July 2012 into one of the UK’s leading Digital Health companies, winning multiple awards and raising in excess of $10M in funding.

Zesty was selected as “1 of the UK’s 30 Finest Early Stage Technology Businesses” by TechCityUK for the Upscale program in 2015 and subsequently Lloyd was voted “1 of the 100 most influential people in HealthTech globally” in 2016 by HotTopics magazine.

Prior to his 5 years in Healthcare, Lloyd had 15 years’ experience building Digital Businesses within 6 Industries - Retail, Travel, Finance, Advertising, Dating and Social Networking. Lloyd studied Business Administration at Coventry University and Corporate Finance at London Business School.

As Senior Technology Adviser, Matthias assists in the appraisal and assessment of new technologies, as part of the investment appraisal and management process. Matthias has more than 20 years experience in the IT and Systems Integration sector, as well as a vast experience in innovation-led technology engineering. Matthias holds a Masters in Mechanical Engineering from the Technology University in Munich, and a degree in Computer Science from Trinity College, Dublin.

Nagy Habib is Professor of Hepatobiliary Surgery, at the Department of Cancer Surgery, at Imperial College London. With principal research activities focusing on the improvement of surgical technologies, Nagy has also been instrumental in the development of remediation and/or cure of diseases of the liver as either a complement or replacement to surgery with particular focus on gene therapy, the use of stem cells and immunotherapy. Nagy has also pioneered novel clinical trials for the treatment of liver cancer. Nagy has extensively published on a wide range of related topics, and is the inventor of, and co-author of the first publication about the use for, radiofrequency in devices used in liver surgery. Awarded by the Advisory Committee for Clinical Excellence, which is given in recognition of exceptional contributions from NHS consultants, Nagy has been named as one of Britain’s top surgeons by the Saturday Times Magazine in 2011.

Peter has over 30 years international senior executive experience in the biotechnology, ethical pharmaceutical, medical devices, FMCG healthcare and B2B industries. Peter founded his Consultancy in 2004 with focus on M&A activity, in/out licensing, strategic alliances and divestments. Experience previously gained as Head of Business Development and Licensing at Pfizer, Pharmacia, Novartis and Nutricia. Peter also raised investment funding and founded in 2008 a generic pharmaceuticals and medical devices import/export joint venture with a local sponsor in the Gulf States.

Rebecca is a paediatric surgeon at the Bristol Royal Hospital for Children.  A member of the Royal College of Surgeons (England) and the British Association of Paediatric Surgeons, she has experience in surgical and medical settings in India, Tanzania, South Africa and Cambodia.  Graduating from The University of Sheffield Medical School, Rebecca also holds a Masters’ in Health Research from the University of Lancaster and the Diploma in Tropical Medicine & Hygiene from the London School of Hygiene & Tropical Medicine. She is an Advanced Paediatric Life Support Instructor and has presented her research at many national and international surgical conferences.

Simon is Chief Executive and board member of the British Hydropower Association (BHA), the only UK trade membership association focusing solely on the unique demands of the hydropower sector.  The BHA actively promotes and campaigns for hydropower in the UK, to increase the awareness of its quality and scope, on a global scale.  Prior to joining the BHA, Simon held senior roles in other consumer and trade membership associations.

A 3-Dimensional designer by qualification, Simon is a non-exec director of a Liverpool based visual communications company, with a career that has embraced international branded drinks, hotels and leisure, electronic entertainment, magazine publishing and internet businesse